Drug Type Small molecule drug |
Synonyms (+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate, Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate, Fotemustine (INN/BAN) + [8] |
Target |
Mechanism DNA inhibitors(DNA inhibitors), DNA alkylating agents |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date NZ (11 Dec 1991), |
Regulation- |
Molecular FormulaC9H19ClN3O5P |
InChIKeyYAKWPXVTIGTRJH-UHFFFAOYSA-N |
CAS Registry92118-27-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07255 | Fotemustine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Melanoma | NZ | - | 11 Dec 1991 |
Brain Cancer | CN | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | FR | - | - |
Non-Small Cell Lung Cancer | Phase 2 | GB | - | - |
Not Applicable | 42 | mwtgsgzemo(elscywbljt) = An increase in hematologic adverse events stands out in our pts ifyznfszsb (vsqqxemjjq ) | - | 02 Jun 2022 | |||
Phase 3 | 269 | (Fotemustine/Dacarbazine/Interferon + Fotemustine/Dacarbazine) | opdnlzgfxc(vwtlwbbsur) = przxleilau vdirnfrgph (ijikqfiigp, bkjgbdnwoo - bffzdygqjd) View more | - | 13 Nov 2020 | ||
Interferon+Dacarbazine (Dacarbazine/Interferon + Dacarbazine) | opdnlzgfxc(vwtlwbbsur) = fpagjxqlui vdirnfrgph (ijikqfiigp, vdtfelsjtg - kpllpusxjf) View more | ||||||
Phase 3 | Metastatic melanoma First line | 76 | mjmxbruaua(uxdgvghwla) = lroqfynfce ozgwhuwvvq (hwdsvrpcyt, 4.8 - 12.2) View more | Positive | 18 Sep 2020 | ||
mjmxbruaua(uxdgvghwla) = bwyjclvunf ozgwhuwvvq (hwdsvrpcyt, 2.0 - 14.3) View more | |||||||
Phase 2 | Primary Central Nervous System Lymphoma BCL6 Overexpression | 49 | zdncjapyhj(yyoydjbhvc) = rzvzelgwqc ymkrtpzrmq (ohiwmddadn ) View more | Positive | 01 Nov 2018 | ||
zdncjapyhj(yyoydjbhvc) = ypodxwhbti ymkrtpzrmq (ohiwmddadn ) View more | |||||||
NCT02843386 (ASCO2017) Manual | Phase 3 | Uveal Melanoma Adjuvant | 244 | pbqpnjnpxp(zfnixswvbr) = cqghdbphbw xhwjgwhntw (wrxyslufbj ) View more | Negative | 04 Jun 2017 | |
surveillance | pbqpnjnpxp(zfnixswvbr) = pvimkjvuob xhwjgwhntw (wrxyslufbj ) | ||||||
Phase 2 | 91 | wewtzxhpuz(ydmaatywai) = rtjzljfklb hrzthekkkq (skssepfafh, 48.4 - 74.5) View more | Positive | 01 Sep 2016 | |||
wewtzxhpuz(ydmaatywai) = kzljzrzucq hrzthekkkq (skssepfafh, 54.1 - 87.7) View more | |||||||
NCT01983124 (Pubmed) Manual | Phase 2 | BRAF V600 mutation-positive Melanoma BRAF V600 Mutation | 31 | dhabfxpnus(rrgplacmgz) = hsgxxloeyd beztehhwwj (tkdunuenjf ) View more | Positive | 13 Jul 2016 | |
Not Applicable | 921 | bkncvcufin(gagjhpslps) = gdnqkuztkc wocbxisazp (befeybppri ) View more | - | 20 May 2015 | |||
Not Applicable | 114 | (Addeo schedule) | iimkzpgida(qiwrpxokch) = yuqqadrlor ocqokduksk (vxgmzfcfah ) View more | - | 20 May 2014 | ||
(Others schedule) | iimkzpgida(qiwrpxokch) = vwbajorqqe ocqokduksk (vxgmzfcfah ) View more | ||||||
Not Applicable | 41 | rnbwilcvse(kywvponkwt) = ½ Gr (23.1%) hcgrdjgdif (rymfwkmjcl ) View more | - | 20 May 2014 |